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Abstract
Introduction: Chronic kidney disease (CKD) is defined as the presence of renal injury that leads 
to the slow and progressive loss of kidney function. 
Aim: To compare audiological tests between patients with CKD receiving different types of 
treatment. 
Material and method: This was a clinical and experimental study. Groups were divided accord-
ing to treatment: hemodialysis (n = 35), peritoneal dialysis (n = 15), and conservative (n = 51), 
and were compared to 27 healthy controls. Patients older than 60 years; those with congenital 
hearing loss, genetic syndromes, and middle-ear infections; and those who had been submitted 
to a kidney transplant were excluded. Audiologic evaluation included pure-tone audiometry, 
transient evoked otoacoustic emissions, and auditory brainstem response (ABR). The variables 
considered were gender, age, diagnosis of arterial hypertension, time since the diagnosis of 
diabetes and hypertension, CKD stage, duration of CKD, and duration of treatment. 
Results: The variables age, presence of arterial hypertension, and time of CKD were statis-
tically significant and controlled. The auditory thresholds measured by pure-tone threshold 
audiometry were worse for the conservative treatment group, and the III-V interval of the 
ABR of the conservative treatment group was significantly greater than that of the hemodi-
alysis groups. 
Conclusion: The conservative treatment group presented worse audiological tests, regardless 
of hypertension and diabetes, reinforcing that patients need to undergo a complete hearing 
assessment for better understanding of the disease and its effects on the auditory system.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier 
Editora Ltda. All rights reserved.
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Introduction
Chronic kidney disease (CKD) is defined as the presence of 
renal injury that leads to the slow and progressive loss 
of kidney function.1
An association between CKD and hearing loss was first 
described in patients with Alport syndrome.2 However, an-
atomical, physiological, pathological, and pharmacological 
similarities between the nephron and stria vascularis of the 
cochlea may explain this association in cases that are not 
related to syndromes or genetic diseases.3,4 Sensorineural 
hearing loss at high frequencies is the most common type in 
patients with CKD, and includes both cochlear impairment 
and lesions to particular portions of the auditory pathway.5-8
However, the influence of CKD treatment on auditory func-
tion is inconclusive,8 and hypertension and diabetes mellitus 
are frequently associated with CKD and hearing loss; these 
variables were not considered when analyzing these findings.
In the present study, the audiological tests between patients 
with CKD receiving different types of treatment were compared 
and associated with hypertension and diabetes mellitus.
Methods
Study population
This was a cross-sectional study conducted in a tertia-
ry referral center. The target population consisted of pa-
tients with CKD from the region around the hospital with a 
non-probabilistic intentional sample. 
The exclusion criteria were: previous kidney transplant, 
congenital hearing loss or middle ear alterations, genetic 
syndromes, history of excessive exposure to noise, histo-
ry of use of ototoxic medications, and age greater than 60 
years. These data were confirmed by the patient’s clinical 
history or medical information. 
Patients were divided into groups according to treat-
ment: hemodialysis (n = 35), peritoneal dialysis (n = 15), 
and conservative (n = 51), as well as 27 healthy subjects.
Audiological assessment
This audiologic evaluation consists of pure-tone audiometry 
(PTA), transient evoked otoacoustic emissions (TEOAEs) and 
auditory brainstem response (ABR).
The PTA was performed by an audiologist in a 
sound-treated room using standard TDH-39 earphones and 
an InteracousticsAD229b audiometer. Audiometric thresh-
olds for air-conduction stimuli in both ears were established 
for frequencies at 250, 500, 1,000, 2,000, 3,000, 4,000, 
6,000, and 8,000 Hz.
TEOAEs measurements were performed using Otody-
namics ILO 288, USB II system with standard settings. The 
stimulus level was set to 84 dB SPL a number of 260 aver-
ages was used. Values < 3 dB amplitude were considered as 
negative.9
For the ABR analysis, the rarefaction click stimulus was 
presented by the 3 Ω insertion phone, with 90 dBnHL inten-
sity and a presentation rate of 20.1 c/s with a band-pass fil-
ter of 100 and 3,000 Hz and average of 2,000 stimuli, using 
Interacoustics EP15 Eclipse. The ABR were captured through 
ECG disposable electrodes (MEDITRACETM 200), with EEG 
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O tratamento da doença renal crônica pode afetar a audição?
Resumo
Introdução: Doença renal crônica (DRC) é definida pela presença de lesão renal levando à 
perda lenta e progressiva da função renal. A influência do tratamento da DRC sobre a audição 
ainda é inconclusiva.
Objetivo: Comparar testes auditivos entre pacientes com DRC submetidos a diferentes tipos de 
tratamento. 
Material e método: Cohort transversal. Os grupos foram divididos de acordo com o tratamento: 
hemodiálise (n = 35), diálise peritoneal (n =15), conservador (n = 51) e 27 pacientes saudáveis 
(controle). Pacientes com idade superior a 60 anos, perda auditiva congênita, síndromes gené-
ticas, infecções de orelha média e transplante renal foram excluídos da pesquisa. A avaliação 
audiológica incluiu audiometria tonal, emissões otoacústicas evocadas transientes e Potencial 
Evocado Auditivo de Tronco Encefálico (PEATE); e as variáveis avaliadas foram: sexo, idade, 
diagnóstico de hipertensão arterial e diabetes, estadiamento da DRC, tempo de diagnóstico do 
diabetes e da hipertensão arterial, duração da DRC e do tratamento.
Resultados: A idade, presença de hipertensão arterial e tempo de DRC foram estatisticamente 
significantes e controlados. O grupo conservador apresentou piores limiares auditivos na audio-
metria tonal e o intervalo III-V do PEATE significativamente maior que o da hemodiálise.
Conclusão: O tratamento conservador mostrou piores resultados na avaliação auditiva, inde-
pendente de diabetes e de hipertensão, reforçando que os pacientes submetidos a tratamento 
para DRC merecem avaliação auditiva completa para melhor compreensão da doença e de seus 
efeitos sobre o sistema auditivo.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier 
Editora Ltda. Todos os direitos reservados.
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conductive paste (Tem 20TM) placed after cleaning the skin 
with ECG/EEG abrasive gel (NUPREP). The impedance level 
was kept between 1 and 3 kΩ for the electrodes; the active 
electrode was positioned in Fz, the reference electrode in 
M1 and M2, and the ground electrode in Fpz.
10,11
Variables
Potential confounders were considered: gender, age, race, 
diagnosis of arterial hypertension (yes/no), time since the 
diagnosis of hypertension, diagnosis of diabetes (yes/no), 
time since the diagnosis of diabetes, CKD stage (1/2/3/4), 
duration of CKD, and duration of treatment.
The outcome hearing impairment was determined as as 
the pure-tone average of audiometric hearing thresholds at 
500, 1,000, 2,000 and 4,000 Hz > 25 dB; all audiometric 
hearing thresholds, classification of negative TEOAEs, and 
parameters of ABR were analyzed.
Statistical analyses
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences (SPSS), release 19.0. Nonparametric 
variables are expressed as the median (minimum-maximum). 
The chi-squared test was used to examine categorical vari-
ables. Comparisons between groups were performed with 
Dunn’s test.
The categorical outcomes (hearing loss and negative 
TEOAEs) were compared by multivariable logistic regression 
Table 1 Comparison of demographic data, comorbidities, and characteristics of chronic kidney disease (CKD) according to groups.
Groups
Control Conservative Peritoneal dialysis Hemodialysis p-value
Male gender 44.1 58.8   40.0   57.1   0.432a
White ethnicity   0.0   7.8   13.3   14.3   0.217a
Arterial hypertension   0.0a 88.0b   66.7b   91.4b < 0.001a
Diabetes mellitus   0.0 28.0   20.0   37.1   0.006a
CKD stage
1   0.0   8.2     0.0     0.0
2   0.0   2.0     0.0     0.0
3   0.0 24.5     0.0     0.0
4   0.0 38.8   0.0     0.0
5   0.0 26.5 100.0 100.0
Age (years)  31 (20-58)a  51(7-60)b   47 (22-57)ab   53 (17-60)b < 0.001b
Duration of hypertension -   8 (0.4-3.2)     5 (1.4-26.3)   11.1 (0.6-3.2)   0.202b
Duration of diabetes - 17.0 (0.6-3.1)   22.6 (18.8-24.9)   16.0 (4.2-25.0)   0.207b
Duration of CKD -   2.4 (0.3-16.9)a     4.2 (1.4-25.3)ab     6.9 (0.6-21.8)b   0.001b
Treatment duration  
of CKD
-   2.5 (0.3-16.9)     2.3 (0.2-5.8)     2.5 (0.1-21.8)   0.484b
a Chi-squared test. 
b Kruskal-Wallis’ test.
Values in the same row followed by different letters differ significantly (p < 0.005) by the Dunn test.
analysis, which was used to calculate adjusted odds ratios 
(ORs) and 95% confidence intervals (CIs) for associations 
with CKD treatment. The numerical outcomes (audiometric 
hearing thresholds and ABR parameters) were compared by 
linear regression with a gamma response, corrected by the 
effect of age and the presence of hypertension. p–values < 
0.05 were considered to be statistically significant.
Ethics
This study was approved by the Ethics Committee of the 
Faculdade de Medicina de Botucatu, under Protocol No. 
157/2007.
Results
The characteristics of patients, comorbidities, CKD stage, 
and other data of the disease, stratified by treatment, were 
listed in Table 1. A statistical difference was observed in 
arterial hypertension, older patients, and duration of CKD.
No differences were observed in the percentage of hear-
ing loss between the various types of treatment (p > 0.05). 
Corrections for hypertension and age were not necessary in 
this case, since the types of treatment were homogeneous. 
However, in other comparisons, this correction was neces-
sary (Tables 2 and 3).
The conservative group had worse hearing thresholds 
when compared to the control group in all frequencies 
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Table 2 Comparison of hearing thresholds at frequencies of 250 Hz to 8 kHz assessed by pure-tone audiometry in each ear 
according to group.
Groups
Ear Frequency Control Conservative Peritoneal dialysis Hemodialysis
Right 250 Hz 5 (0-15)a 10 (5-80)b 15 (0-40)ab 15 (0-110)ab
500 Hz 5 (0-15)a 10 (0-80)b 15 (0-45)ab 10 (0-110)ab
1 kHz 5 (0-15)a 10 (0-80)b 10 (0-40)ab 5 (0-120)ab
2 kHz 5 (0-10)a 10 (0-85)b 10 (0-35)ab 10 (0-120)ab
3 kHz 5 (0-15)a 15 (0-85)b 10 (0-35)ab 15 (0-120)ab
4 kHz 5 (0-15)a 25 (0-90)b 20 (10-45)ab 20 (0-120)ab
6 kHz 10 (0-25)a 25 (0-105)b 20 (0-55)a 25 (0-120)ab
8 kHz 10 (0-15)a 30 (0-95)b 15 (0-65)a 35 (0-120)ab
Left 250 Hz 5 (0-15)a 10 (5-100)b 15 (0-60)b 10 (0-110)ab
500 Hz 5 (0-15)a 15 (0-120)b 10 (0-60)b 10 (0-105)ab
1 kHz 5 (0-10)a 10 (0-120)b 10 (0-65)b 10 (0-110)b
2 kHz 5 (0-10)a 10 (0-120)b 10 (0-50)b 10 (0-110)b
3 kHz 5 (0-10)a 15 (0-120)b 15 (0-45)b 15 (0-115)b
4 kHz 10 (0-15)a 20 (0-115)b 10 (0-50)ab 20 (0-120)b
6 kHz 10 (0-15)a 30 (0-100)b 35 (5-90)b 25 (0-120)b
8 kHz 10 (0-20)a 25 (0-120)ab 25 (5-90)b 30 (0-120)ab
a Values were expressed as median (range). 
b Corrected for age and hypertension. 
Values in the same row followed by different letters differ significantly (p < 0.005) by the Wald test.
Table 3 Comparison of the parameters of the brainstem auditory response (ABR) in each ear according to group.
ABR Groups Grupos
Ear Control Conservative Peritoneal dialysis Hemodialysis
Right I 1.37 (1.17-1.60)a 1.40 (1.17-1.90)a 1.40 (1.20-1.57)a 1.47 (0.93-1.83)a
III 3.47 (3.23-3.90)a 3.60 (3.27-4.07)a 3.67 (3.37-3.90)a 3.62 (3.20-4.53)a
V 5.50 (5.27-5.93)a 5.77 (5.20-6.60)a 5.77 (5.27-6.23)a 5.70 (5.13-6.60)a
I-III 2.10 (1.83-2.43)a 2.17 (1.77-2.73)a 2.23 (2.00-2.43)a 2.20 (1.73-2.70)a
III-V 2.07 (1.50-2.40)ab 2.13 (1.73-2.80)a 2.10 (1.60-2.73)ab 2.07 (1.87-2.53)b
I-V 4.20 (3.77-4.67)a 4.30 (3.80-5.43)a 4.33 (3.97-4.97)a 4.25 (3.77-4.77)a
Left I 1.37 (1.20-1.53)a 1.37 (1.17-1.87)a 1.40 (1.17-1.57)a 1.43 (1.17-2.00)a
III 3.49 (3.20-3.70)a 3.57 (3.37-4.07)a 3.62 (3.43-3.97)a 3.67 (3.27-4.43)a
V 5.47 (5.27-5.90)a 5.73 (5.30-7.43)a 5.69 (5.47-6.23)a 5.80 (5.27-6.43)a
I-III 2.12 (1.77-2.47)a 2.20 (1.77-2.80)a 2.25 (2.03-2.63)a 2.27 (2.00-2.90)a
III-V 2.07 (1.73-2.37)ab 2.10 (1.83-3.67)a 2.09 (1.67-2.30)ab 2.09 (1.77-2.27)b
I-V 4.12 (3.80-4.67)a 4.33 (3.87-5.87)a 4.35 (4.03-4.90)a 4.33 (3.90-5.00)a
ABR, auditory brainstem response.
a Values were expressed as median (range).
b Corrected for age and hypertension. 
Values in the same row followed by different letters differ significantly (p < 0.005) by the Wald test.
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Conclusion
The conservative treatment group presented worse hearing 
threshold and abnormal ABR, reinforcing that patients un-
dergoing treatment for chronic renal disease need a com-
plete hearing assessment for better understanding of the 
disease and its effects on the auditory system.
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tested. In contrast, no significant difference was observed 
between the other treatments (Table 2).The percent-
age of negative TEOAEs did not differ significantly among 
the groups (p > 0.05).
In the ABR, the conservative group had bilateral sym-
metric increased III-V interval compared to the hemodialysis 
group, with a statistically significant difference (Table 3).
Discussion
The present study was motivated by the inconclusive litera-
ture findings regarding the effect of the type of CKD treat-
ment – conservative, peritoneal dialysis, and hemodialysis 
– on auditory acuity, and by the possible correlations of ar-
terial hypertension and diabetes,12,13 which are frequently 
associated with CKD and hearing loss. 
To this end, certain criteria were adopted to reduce 
the interference of other factors with auditory alterations. 
Subjects older than 60 years were excluded, since 25% of 
individuals in this age range show alterations in auditory 
tests due to age.8 Individuals submitted to previous kidney 
transplantation were excluded due to the use of immuno-
suppressive drugs pre- and post-transplantation, which may 
exert an ototoxic effect.5,14 Additionally, transplantation is 
usually the treatment of last resort, and thus patients have 
been submitted to other treatments, hindering the analysis 
of their effects. 
Arterial hypertension and diabetes mellitus are the main 
causes or consequences of CKD,1 and therefore were main-
tained in the study and considered in the data analysis.
Possible changes in hearing assessment have been de-
scribed by some authors soon after dialysis; these findings 
could be attributed to the drugs used or to the ionic concen-
trations of sensory cells.15,16 However, most studies did not 
demonstrate a significant effect of a single dialysis session 
on hearing.15-18 For this reason, and because patients are 
usually tired and stressed after a dialysis session, subjects 
were not evaluated at this time. 
When the type of CKD treatment was considered, the 
subgroups were found to be similarly affected by hearing 
loss, as also reported by Mancini et al.19 and by Nikolopou-
los et al.20 However, the results show that audiometry find-
ings of the conservative group were significantly worse than 
those of the control group. The authors believe that the 
conservative therapy may cause accumulation of toxic sub-
stances in the bloodstream, since these substances are not 
efficiently eliminated by the kidneys or by dialysis, conse-
quently impairing auditory functions.
The peritoneal dialysis group was least affected by neg-
ative TEOAEs,  and the hemodialysis group was the most af-
fected, although the difference was not significant, as also 
reported by Ozturan & Lam15 and by Naderpour et al.21 
Although hemodialysis may be a more aggressive method 
regarding the cochlea by possibly causing ionic changes in 
the cell membrane,19,20,22,23 this finding was not observed 
in the present study when using TEOAEs.
In the ABR, the conservative group differed from the 
hemodialysis group, with an increased III-V interval, sug-
gesting injury in central portions of the brainstem auditory 
pathway.24
Could the type of treatment for chronic kidney disease affect the auditory system? 59
18. Gierek T, Markowski J, Kokot F, Paluch J, Wiecek A, Klimek D. 
Electrophysiological examinations (ABR and DPOAE) of hearing 
organ in hemodialysed patients suffering from chronic renal 
failure. Otolaryngol Pol. 2002;56:189-94.
19. Mancini M, Dello Strologo L, Bianchi P, Tiere L, Rizonni G. Sen-
sorineural hearing loss in patients reaching chronic renal failu-
re in childhood. Pediatr Nephrol. 1996;10:38-40.
20. Nikolopoulos TP, Kandiloros DC, Segas SV, Nomicos PN, Fereki-
dis EA, Michelis KE, et al. Auditory function in young patients 
with chronic renal failure. Clin Otolaryngol. 1997;22:222-5.
21. Naderpour M, Mortazavi F, Jabbari-Moghaddam Y, Sharifi-Mo-
ghaddam MH. Auditory brain stem response and otoacoustic 
emission results in children with end-stage renal disease. Int 
J Pediatr Otorhinolaryngol. 2011;75:704-7.
22. Johnson DW, Wathen RL, Mathog RH. Effects of hemo-
dialysis on hearing threshold. ORL J Otorhinolaryngol Relat 
Spec.1976;38:129-39.
23. Erkoç MF, Bulut S, İmamoğlu H, Gümüş C, Kayataş M. CT asses-
sment of bone remodeling in the otic capsule in chronic renal 
failure: association with hearing loss. AJR Am J Roentgenol. 
2013;200:396-9.
24. Jakić M, Mihaljević D, Zibar L, Jakić M, Kotromanović Z, Rogul-
jić H. Sensorineural hearing loss in hemodialysis patients. Coll 
Antropol. 2010;34:165-71.
